It has been suggested that the more favourable response to chemotherapy of HBOC ovarian tumours is related to their increased sensitivity to DNA-damaging agents, such as platinum-containing regimen since in the absence of BRCA1/2 function, there is a deficiency in the homologous-recombination repair, resulting in an impaired ability of tumour cells to repair platinum-induced double-strand breaks [2, 6]. Here, BRCA1 is linked to neoplasm.